

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

SN12C

RRID:CVCL_1705

Type: Cell Line

Proper Citation

RRID:CVCL_1705

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1705

Proper Citation: RRID:CVCL_1705

Description: Cell line SN12C is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Renal cell carcinoma

Defining Citation: [PMID:2041050](#), [PMID:2706827](#), [PMID:3335022](#), [PMID:3731078](#), [PMID:8053494](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:11146448](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20952505](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31733513](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SN12C

Synonyms: SN-12C, SN12 C

Cross References: BTO:BTO_0004221, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, cancercellines:CVCL_1705, Cell_Model_Passport:SIDM00094, ChEMBL-Cells:ChEMBL3307518, ChEMBL-Targets:ChEMBL614054, CLS:305629,

Cosmic:687942, Cosmic:849372, Cosmic:897464, Cosmic:905979, Cosmic:974307, Cosmic:1044262, Cosmic:1092636, Cosmic:1175852, Cosmic:1305377, Cosmic:1312365, Cosmic:1998479, Cosmic-CLP:905979, DepMap:ACH-002199, EGA:EGAS000001000978, GDSC:905979, GEO:GSM2097, GEO:GSM50230, GEO:GSM50294, GEO:GSM579204, GEO:GSM579205, GEO:GSM579404, GEO:GSM743485, GEO:GSM750840, GEO:GSM799376, GEO:GSM799439, GEO:GSM844695, GEO:GSM844696, GEO:GSM847160, GEO:GSM1153449, GEO:GSM1178609, GEO:GSM1178610, GEO:GSM1181307, GEO:GSM1181325, GEO:GSM1670459, GEO:GSM2124685, IARC_TP53:18075, KCLB:80025, NCI-DTP:SN12C, Pharmacodb:SN12C_1428_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1705, PubChem_Cell_line:CVCL_1705, SKY/M-FISH/CGH:2804, Wikidata:Q54955018

ID: CVCL_1705

Record Creation Time: 20220427T221550+0000

Record Last Update: 20260913T010053+0000

Ratings and Alerts

No rating or validation information has been found for SN12C.

No alerts have been found for SN12C.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hillen H, et al. (2024) A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. Molecular cancer therapeutics, 23(1), 3.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Hwang C, et al. (2024) TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment. The American journal of pathology, 194(7), 1306.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Nakazawa K, et al. (2023) Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. *Cancer research communications*, 3(10), 2030.

Song Z, et al. (2022) Circ_0072995 drives cervical cancer development by regulating the miR-29a/WDR5 axis. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology*, 42(7), 3342.

Bi J, et al. (2019) Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. *Cell metabolism*, 30(3), 525.

Macpherson JA, et al. (2019) Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation. *eLife*, 8.